Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. - Wikidata - wikimedia - TriplyDB

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

http://www.wikidata.org/entity/Q46713770

about

Immunotherapy of systemic sclerosis Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities Tie2 as a novel key factor of microangiopathy in systemic sclerosis.Effect of tyrosine kinase inhibitors, imatinib and nilotinib, in murine lipopolysaccharide-induced acute lung injury during neutropenia recovery.Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Tyrosine kinases in inflammatory dermatologic disease.Targeting the PDGF signaling pathway in the treatment of non-malignant diseases.Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis.Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Platelet-derived serotonin links vascular disease and tissue fibrosis.c-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts.Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis.Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.The Effect of rhCygb on CCl4-Induced Hepatic Fibrogenesis in Rat.Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.CD90+ mesothelial-like cells in peritoneal fluid promote peritoneal metastasis by forming a tumor permissive microenvironment.Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis.Noncanonical transforming growth factor beta signaling in scleroderma fibrosis Agonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro.The immunology of fibrosis: innate and adaptive responses.Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis.Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.Evidence-based management of rapidly progressing systemic sclerosis.Possible strategies for anti-fibrotic drug intervention in scleroderma.Deconstructing fibrosis research: do pro-fibrotic signals point the way for chronic dermal wound regeneration?Fibroblast abnormalities in the pathogenesis of systemic sclerosis.Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.The evolving pharmacotherapy of pulmonary fibrosis.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Modulation of d-galactosamine/lipopolysacharride-induced fulminant hepatic failure by nilotinib.Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits.Nilotinib induces apoptosis and autophagic cell death of activated hepatic stellate cells via inhibition of histone deacetylases.Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.

P2860

Q24634395-46882818-DC3F-4B37-A0CE-FDF974B65427 Q28476104-75A6891C-C0BB-4F63-A9E0-53B9168D2FDE Q33730294-DCE310AC-7200-4A3B-99E6-3D74A2D8A76D Q33751025-65F87FA6-E162-4A59-8578-4BFEE3598839 Q34027197-1489762D-82E1-4E8D-B88D-88D59073869A Q34166503-2A0E23DC-DD71-4D01-BA05-887040716E5B Q34352802-D312C732-A0C1-4E7B-91B5-8B017D20F17E Q34485231-B5780FA1-EE91-49C0-9BF5-EDE139A21267 Q34906164-19AC0DF7-B88E-4E2A-A913-2ED6FA66C298 Q34973681-0873DCF3-237D-49C3-B2A1-D40733F8F868 Q35602670-9BB42CEC-A789-4CAD-B8FA-046F0ACE4E0B Q35803480-E6BA8696-7BF8-4BC3-9666-6164D36B05E1 Q35863725-E9449EB0-D98B-4A52-850D-5AAC817CE50B Q35961706-CD40776E-DFE2-46B8-AB6A-2C91B1604E02 Q36389384-F1187B48-3308-430F-A29B-49321105F625 Q36719690-BDC7B57B-8379-43EC-A3C5-C1F2F06CE485 Q37075998-DA4C2E47-9C4C-4B4A-9C24-8D168796803C Q37305155-EBC47BA0-BC6C-4E90-970C-58E2D1BA8004 Q37402787-07D36427-EEDE-43EF-AD56-F8690477265A Q37492625-5CE7D8B2-5D93-4B84-B4DD-BF07D9144028 Q37500419-ADAF2D91-139D-448C-A0A2-FA201248CAB3 Q37523472-776E76F2-9037-4D81-8818-E8DAE60BCF58 Q37588466-FD9015C1-A1C1-41D4-AB4C-509CB6262B12 Q37629847-2C3225C2-113F-493C-A066-845C2AA36545 Q37682484-7A2C18CE-BF0C-4BE0-A19E-B570D46847A8 Q37690287-2978D175-9F5A-4465-B7D0-74F720BE28CA Q37761374-A0E7CCE3-7634-442D-B49C-2BCD78DDDD16 Q37763779-10DA091E-4F3D-48AA-A604-FB6E883F3BD3 Q37864123-43A115D3-B266-4E14-B083-8F41E81064C8 Q37866690-B4E90E62-6697-40B4-84B0-FE354DAD35C2 Q37905795-B06F8311-F3C8-452F-B334-0EF0CC33B731 Q37930709-37A4838A-1E60-48E3-BF16-A400E4DA19D7 Q38067464-F887E86B-9F0D-4DAD-97C3-582969D503F1 Q38069617-C17BDE75-CE5C-4763-92B7-EA73DACF0E8A Q38580461-99CB84F6-ACE9-49C5-9DDB-02394A6ED513 Q38997142-1A808DBF-FA53-4C21-A8E1-0E7BFF1FCFDA Q39110979-18C7AEBF-CF2C-4FEA-8643-07A37E34B8DA Q39180227-FA0A9D94-8F66-48BB-9DCB-187BE1DA3FB5 Q41095169-BE01B9BB-1102-4564-969B-DDDADB0B2ADF Q41347489-D2ED8CBE-F3E4-408B-98B4-50FD10DDA055

P2860

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis.

http://www.wikidata.org/entity/Q46713770

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@en

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@nl

type

label

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@en

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@nl

prefLabel

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@en

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@nl

P1433

Q46713770-3700FC79-5702-4FD2-BFDF-91C26BD6028A

P1476

Q46713770-7796F54A-36A8-4632-868F-A35603897D0E

P2093

Q46713770-06848002-C8B3-44E2-9098-5FAE3B462E74

Q46713770-11C612BA-30F8-4C3D-A873-0ED269BD7EB6

Q46713770-1490BDE0-B469-47CE-ABD5-55F2456FD2C7

Q46713770-17D90B18-01D0-49A9-AFE5-583F67853FE5

Q46713770-2053D8E7-D6DE-4BB4-BE17-088F50A95918

Q46713770-3A86881C-75AD-4E1B-9930-3D5DD1DF446C

Q46713770-3DDA390D-E736-4750-953F-39E2798BBE08

Q46713770-6191A7F1-E18A-4BF5-8256-623BC895793C

Q46713770-8575F1C5-80F0-4560-97C1-D4E82BA1C087

Q46713770-9B86A952-B219-4091-A7EC-46EAB379E421

P304

Q46713770-34450063-45B8-4DBA-8E43-609B457AF7CC

P31

Q46713770-34F26BFB-2324-4F37-9278-A62139F42D9A

P356

Q46713770-C4FB73D7-0EBF-447D-A001-4D98BEE4CD61

P407

Q46713770-AE0E85A8-58CB-49FF-AEA9-B73088CA96F3

P433

Q46713770-66E14147-35DD-4AAF-A119-A8646FBD0084

P478

Q46713770-B654C9C0-5E02-47B3-B9EC-A97E65AD0642

P50

Q46713770-3FDECE74-8151-4F70-952C-9591DC7D7F4D

P577

Q46713770-FCD28E08-7477-47EA-9BF3-D0786B06DAE8

P5875

Q46713770-C4C5D02F-4C7F-4B00-8E14-AF72CEA731B8

P698

Q46713770-324E3B74-8EBA-4D75-AB2B-A810D8CBF235

P356

P1433

P1476

Dual inhibition of c-abl and P ...... treatment of dermal fibrosis.

@en

P2093

Alfiya Akhmetshina

http://www.w3.org/2001/XMLSchema#string

Astrid Jüngel

http://www.w3.org/2001/XMLSchema#string

Britta Maurer

http://www.w3.org/2001/XMLSchema#string

Clara Dees

http://www.w3.org/2001/XMLSchema#string

Jochen Zwerina

http://www.w3.org/2001/XMLSchema#string

Jörg H W Distler

http://www.w3.org/2001/XMLSchema#string

Margarita Pileckyte

http://www.w3.org/2001/XMLSchema#string

Oliver Distler

http://www.w3.org/2001/XMLSchema#string

Roland Axmann

http://www.w3.org/2001/XMLSchema#string

Steffen Gay

http://www.w3.org/2001/XMLSchema#string

P304

2214-2222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1096/FJ.07-105627

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5525027

http://www.w3.org/2001/XMLSchema#string

P698

18326784

http://www.w3.org/2001/XMLSchema#string